Biotech investors, industry members and academic innovators are invited to attend ‘Biotech by Lake 2021 Investor Summit’, hosted by Chemistry of Life Processes Institute (CLP) at Northwestern. The third annual program will highlight next-generation therapies and approaches to understanding neurodegenerative diseases. Presentations will provide an in-depth look at breakthrough therapies and new technologies for earlier and more accurate diagnosis of Alzheimer’s disease, upper motor neuron diseases and other disorders. The online program will feature 17 academic, investment and industry experts. Panel discussions will highlight the hottest trends and investment opportunities in neuroscience therapies and technologies. The online summit, presented in collaboration with Oppenheimer & Co., Inc. and BioCentury, Inc., will take place on June 22, 2021, from 9-11:45 a.m. CST.
Click here to register.
Program:
Faculty presenters:
- Neil L. Kelleher, PhD, Interim Director, Chemistry of Life Processes Institute, Walter and Mary E. Glass Professor of Molecular Biosciences; Professor of Chemistry; and Professor, Biochemistry and Molecular Genetics and Medicine; Faculty Director, Northwestern Proteomics (HOST)
- William Klein, PhD, Professor of Neurobiology, Weinberg College of Arts and Sciences – “Next Generation Vaccines Targeting the Cause of Alzheimer’s Disease”
- Yevgenia Kozorovitskiy, PhD, Soretta and Henry Shapiro Research Professor of Molecular Biology, Associate Professor of Neurobiology, Weinberg College of Arts and Sciences – “High Precision Screens for Pharmacological Traction of Neuroplasticity”
- Pembe Hande Ozdinler, PhD, Associate Professor of Neurology, Feinberg School of Medicine – “Improving Success Rate of Clinical Trials by Proteomics”
- Richard B. Silverman, PhD, Patrick G. Ryan/Aon Professor, Professor of Chemistry and Molecular Biosciences, Weinberg School of Arts and Sciences – “Upper Motor Neuron Diseases and Alzheimer’s: Serious Diseases Addressed in the Silverman Group”
Corporate presenters:
- Casper Hoogenraad, PhD, Vice President, Head of Neuroscience Research, Genentech
- Sean M. Smith, PhD, Executive Director of Neuroscience Discovery, Merck & Co.
‘Hot Topics in Neurological Disorder Therapeutics and Technologies’ panelists:
- Selina Koch, PhD, Executive Editor, BioCentury, Inc.(Moderator)
- Sarah Bhagat, PhD, General Partner, Sofinnova Investments
- Ginger S. Johnson, PhD, Chief Executive Officer, Cello Health BioConsulting
- Norbert Riedel, PhD, Chief Executive Officer, Aptinyx Inc.
- Myung Shin, PhD, Executive Director and Head of Early Discovery Genetics, Genetics and Pharmacogenomics, Merck & Co., Inc.
‘Financing and Investing in Neurological Science Biotech’ panel discussion investment experts:
- Jay Olson, CFA, Research Analyst, Oppenheimer & Co. (Moderator)
- Jamil M. Beg, Partner, 5AM Ventures
- Margarita Chavez, JD, Managing Director, AbbVie Ventures
- Michael Margolis, R Ph, Managing Director, Oppenheimer & Co.
- Jingwen Wang, PhD, Portfolio Manager, Verition Fund Management, LLC
Media Contact: Lisa La Vallee, lisa.lavallee@northwestern.edu